BioSpace News Archive

Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019

AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action

March 22, 2019
·
2 min read
Teva Selects Genedata Biologics to Support Next-generation Biopharmaceuticals R&D

Genedata Biologics® streamlines Teva’s R&D workflows and increases operational efficiency

March 22, 2019
·
4 min read
Deals

Evotec AG To Report Fiscal Year 2018 Results On 28 March 2019

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

March 22, 2019
·
3 min read
Drug Development

Now, What’s Next in Alzheimer’s? For Biogen and Eisai, Another Phase III Trial

The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?

March 22, 2019
·
5 min read
·
Mark Terry
Biotech Bay

Biotechs by the Bay Boom With Business Bounty

When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.

March 22, 2019
·
4 min read
·
Alex Keown
Pharm Country

A Smart Toilet Seat to Detect Congestive Heart Failure

Researchers at the Rochester Institute of Technology have developed a toilet seat with biometric sensors in it. The primary purpose (the Number 1 purpose?) is to monitor an individual’s cardiovascular system.

March 22, 2019
·
4 min read
·
Mark Terry
Antiepileptics increase the risk of pneumonia among persons with Alzheimer’s disease

People with Alzheimer’s disease using antiepileptic drugs have twice the risk of pneumonia compared to non-users, a new study from the University of Eastern Finland shows.

March 22, 2019
·
1 min read
Drug Development

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials

March 22, 2019
·
4 min read
Deals

BioArctic – Statement regarding today’s trading halt

BioArctic AB comments on the decision by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price.

March 22, 2019
·
4 min read
Drug Development

Conatus Pharma Stock Craters After 3rd Failed NASH Trial

In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.

March 22, 2019
·
3 min read
·
Mark Terry